Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus

Abstract

AimTo evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of a novel, oral glucagon receptor antagonist, LGD‐6972, in healthy subjects and subjects with type 2 diabetes (T2DM).MethodsIn the single ascending dose study, LGD‐6972 (2‐480 mg) was administered to healthy subjects (n = 48) and T2DM subjects (n = 8). In the multiple ascending dose study, healthy subjects (n = 12) received a dose of 15 mg LGD‐6972 and T2DM subjects (n = 36) received doses of 5, 10 or 15 mg of LGD‐6972 daily for 14 days.Results LGD‐6972 had linear plasma pharmacokinetics consistent with once‐daily dosing that was comparable in healthy and T2DM subjects. Dose‐dependent decreases in fasting plasma glucose were observed in all groups with a maximum of 3.15 mmol/L (56.8 mg/dL) on day 14 in T2DM subjects. LGD‐6972 also reduced plasma glucose in the postprandial state. Dose‐dependent increases in fasting plasma glucagon were observed, but glucagon levels decreased and insulin levels increased after an oral glucose load in T2DM subjects. LGD‐6972 was well tolerated at the doses tested without dose‐related or clinically meaningful changes in clinical laboratory parameters. No subject experienced hypoglycaemia.ConclusionInhibition of glucagon action by LGD‐6972 was associated with decreases in glucose in both healthy and T2DM subjects, the magnitude of which was sufficient to predict improvement in glycaemic control with longer treatment duration in T2DM patients. The safety and pharmacological profile of LGD‐6972 after 14 days of dosing supports continued clinical development.

Targeting hepatic glucose metabolism in the treatment of type 2 diabetes

“…The orally available Bay 27-9955 (Bayer) decreased short-term fasting glucose levels without exhibiting any prominent side effects 37 , but was no longer pursued for clinical development for undisclosed reasons. LGD-6972 (Ligand Pharmaceuticals) similarly demonstrated a dose-dependent decrease in fasting glucose in normal and diabetic subjects and favorable safety profiles in a phase 1b clinical study, and a phase II trial is currently underway to better assess its safety and efficacy 36 . In addition, once daily dosing with PF-06291874 (Pfizer) decreased fasting and postprandial glucose levels in patients on metformin, with or without combined treatment with a sulfonylurea, for up to 28 days 35 .…”

Efficacy and safety of the glucagon receptor antagonist PF‐06291874: A 12‐week, randomized, dose‐response study in patients with type 2 diabetes mellitus on background metformin therapy

“…Early clinical trials evaluating GRAs show that these agents reduce fasting plasma glucose (FPG) and glycosylated haemoglobin (HbA1c) levels in T2DM …”

A first‐in‐human pharmacodynamic and pharmacokinetic study of a fully human anti‐glucagon receptor monoclonal antibody in normal healthy volunteers

“…Based on the fact that hyperglucagonaemia contributes to fasting and postprandial hyperglycaemia in people with type 2 diabetes (T2D), glucagon and the glucagon receptor have been investigated as potential targets for diabetes control . Clinical trials with small molecule glucagon receptor antagonists in patients with T2D treated for up to 24 weeks have demonstrated a significant decrease in fasting glucose, postprandial glucose and HbA1c, without significant hypoglycaemia . Reversible increases in LDL‐cholesterol and elevated serum hepatic aminotransferases levels have also been reported .…”